ADVFN US – Market Content Editor
-

HydroGraph Opens Texas Headquarters as 360-Ton Graphene Manufacturing Expansion Advances
HydroGraph is expanding its U.S. production footprint with an Austin headquarters capable of producing up to 30 tons of pristine graphene annually and a larger Bellville facility expected to begin operations in 2027. Key Investor Takeaways Why HGRAF Stock Is in Focus HydroGraph has completed the opening of its Texas headquarters as it advances a…
-

Anavex Life Sciences Faces September Board Vote as Blarcamesine Regulatory Strategy Advances
Anavex is asking shareholders to re-elect its six nominees at the September 24 annual meeting as activist investor PVG seeks board control during a leadership transition and a critical period for the company’s CNS pipeline. Key Investor Takeaways Why AVXL Stock Is in Focus Anavex Life Sciences is heading toward a contested September shareholder vote…
-

1606 Corp. Engages MDM Group to Market 55 MW AI Infrastructure Site in East Texas
The success-fee engagement is designed to connect 1606 Corp.’s planned Lufkin acquisition with AI infrastructure operators, capacity buyers and potential joint venture partners while the company works toward completing the property transaction. Key Investor Takeaways Why CBDW Stock Is in Focus 1606 Corp. has added MDM Group to its effort to commercialize a planned AI…
-

Linkage Global Evaluates Hotel Acoustic Wellness Technology Expansion With No Partnerships Yet Signed
Linkage Global is exploring hotel deployments for its AI-enabled acoustic wellness technology, but the initiative remains at an evaluation stage with no commercial agreements currently in place. Key Investor Takeaways Why UZX Stock Is in Focus Linkage Global is assessing whether its acoustic wellness technology can be deployed within hotels as part of a broader…
-

Katapult Completes Aaron’s and CCFI Business Combination, Creating $4 Billion Nonprime Financial Platform
The all-stock transaction combines three businesses under Katapult Holdings, with the enlarged company reporting more than $4 billion in 2025 pro forma revenue and more than $460 million in pro forma adjusted EBITDA. Key Investor Takeaways Why KPLT Stock Is in Focus Katapult has completed its previously announced all-stock combination with Aaron’s and CCFI, transforming…
-

Fabric.AI Targets CES 2027 for First Neural I/o MicroLED Optical Interconnect Demonstration
Fabric.AI and Kopin say development remains on schedule for a working CES demonstration, providing the first public test of their MicroLED-based approach to AI infrastructure connectivity. Key Investor Takeaways Why FABC Stock Is in Focus Fabric.AI has established January’s CES 2027 as the next major milestone for Neural I/o, confirming that it expects to publicly…
-

Global Engine Group Advances Space-to-AI Edge Infrastructure Platform With Angkasa-X Collaboration
The agreement moves Global Engine Group beyond its May memorandum of understanding toward a Sarawak proof-of-concept combining satellite ground stations, edge data center infrastructure and local AI data processing. Key Investor Takeaways Why GLE Stock Is in Focus Global Engine Group is moving its proposed collaboration with Angkasa-X into a more defined development phase as…
-

Fort Technology Signs Logia USA Acquisition Deal to Enter Data Center Fuel Integrity Market
The proposed acquisition gives Fort Technology a 50.1% controlling stake in an early-stage U.S. fuel integrity business, backed by a milestone-based $2 million credit facility and a structure that could materially reduce Fort’s ownership if Logia USA reaches higher sales thresholds. Key Investor Takeaways Why FRTT Stock Is in Focus Fort Technology’s Logia USA acquisition…
-

Neuronetics Narrows Q2 Loss as Greenbrook Growth Drives 9% Revenue Increase
Neuronetics improved margins, reached positive adjusted EBITDA and lowered its 2026 operating expense outlook, although NeuroStar revenue declined during the quarter. Key Investor Takeaways Why STIM Stock Is in Focus Neuronetics’ Q2 loss narrowed substantially as growth at its Greenbrook clinics, margin expansion and lower expenses moved the company closer to profitability. Total revenue increased…
-

Mereo BioPharma Extends Cash Runway Into Late 2027 as Alvelestat Phase 3 Partnership Advances
The rare-disease biotech cut its quarterly net loss while a new Sentynl agreement could provide $40 million in upfront and R&D payments and funding for alvelestat’s planned Phase 3 study. Key Investor Takeaways Why MREO Stock Is in Focus Mereo BioPharma’s updated cash runway into late 2027 gives the clinical-stage company additional operating visibility while…